News

KPG-818 Found Safe to Enter Clinical Trials for SLE, Blood Cancers

Positive early Phase 1 clinical data in healthy volunteers support Kangpu Biopharmaceuticals’ plan to advance KPG-818 into clinical trials in patients with systemic lupus erythematosus (SLE) or blood cancers. KPG-818 is a small molecule designed to inhibit the activity of the CRL4-CRBN protein complex. CRBN, or cereblon, is a…

PredictImmune to Develop and Commercialize Prognostic Tool for SLE

PredictImmune is planning to expand its pipeline with the development of new strategies to support personalized care for people with systemic lupus erythematosus (SLE) and other inflammatory diseases. This follows the U.K.-based company’s acquisition of worldwide licensing rights over Cambridge Enterprise’s algorithms and software. The new deal…